← Back to All US Stocks

Mannkind Corp. (MNKD) Stock Fundamental Analysis & AI Rating 2026

MNKD Nasdaq Pharmaceutical Preparations DE CIK: 0000899460
Updated This Month • Analysis: May 8, 2026 • SEC Data: 2026-03-31
Combined AI Rating
SELL
74% Confidence
NEUTRAL
STRONG SELL
85% Conf
HOLD
64% Conf

📊 MNKD Key Takeaways

Revenue: $90.2M
Net Margin: -18.4%
Free Cash Flow: $-7.2M
Current Ratio: 1.87x
Debt/Equity: N/A
EPS: $-0.05
AI Rating: STRONG SELL with 85% confidence
Mannkind Corp. (MNKD) receives a SELL rating with 74% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $90.2M, net profit margin of -18.4%, Mannkind Corp. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete MNKD stock analysis for 2026.

Is Mannkind Corp. (MNKD) a Good Investment?

Claude

MannKind is operationally unprofitable with negative stockholders' equity (-$59.2M) and unsustainable cash burn (-$7.2M FCF). Despite 22% revenue growth, the company operates at -18.4% net margin and cannot cover debt service from operations (-0.2x interest coverage), indicating a path toward insolvency unless profitability is achieved imminently.

ChatGPT

Revenue growth is strong and operating profitability has turned positive, producing modest free cash flow and adequate liquidity. However, net margins remain thin, equity is negative, and leverage is meaningful, leaving limited cushion if growth or margins soften. Sustained cash generation and margin expansion are needed to repair the balance sheet and improve durability.

Why Buy Mannkind Corp. Stock? MNKD Key Strengths

Claude
  • + Revenue growing 22.2% YoY shows commercial traction
  • + Adequate short-term liquidity with 1.87x current ratio
  • + Cash reserves of $52.8M provide near-term runway
ChatGPT
  • + 22.2% YoY revenue growth indicating solid demand momentum
  • + Positive operating income with 11.1% margin and positive FCF
  • + Adequate liquidity (current ratio 1.7x; quick ratio 1.5x)

MNKD Stock Risks: Mannkind Corp. Investment Risks

Claude
  • ! Negative stockholders' equity of -$59.2M indicates technical insolvency
  • ! Operating cash flow negative at -$5.4M; company cannot fund operations from business
  • ! High debt burden of $318.7M with no operational cash to service; interest coverage at -0.2x
  • ! Net margin deteriorating at -18.4%; each dollar of revenue loses 18+ cents
  • ! EPS worsening sharply at -80% YoY decline
  • ! Cash burn rate suggests 4-5 years runway; requires near-term inflection to profitability
ChatGPT
  • ! Negative stockholders' equity and sizable long-term debt load
  • ! Very thin net margin (1.7%) and sharply lower diluted EPS
  • ! Interest coverage only moderate at 4.5x, sensitive to margin compression

Key Metrics to Watch

Claude
  • * Path to operating profitability and positive operating cash flow
  • * Quarterly cash burn rate relative to remaining cash runway
  • * Revenue growth sustainability and contribution margin expansion
  • * Debt refinancing or equity raise needs as cash depletes
ChatGPT
  • * Net margin
  • * Operating cash flow

Mannkind Corp. (MNKD) Financial Metrics & Key Ratios

Revenue
$90.2M
Net Income
$-16.6M
EPS (Diluted)
$-0.05
Free Cash Flow
$-7.2M
Total Assets
$744.4M
Cash Position
$52.8M

💡 AI Analyst Insight

Mannkind Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

MNKD Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -1.8%
Net Margin -18.4%
ROE N/A
ROA -2.2%
FCF Margin -8.0%

MNKD vs Healthcare Sector: How Mannkind Corp. Compares

How Mannkind Corp. compares to Healthcare sector averages

Net Margin
MNKD -18.4%
vs
Sector Avg 12.0%
MNKD Sector
ROE
MNKD 0.0%
vs
Sector Avg 15.0%
MNKD Sector
Current Ratio
MNKD 1.9x
vs
Sector Avg 2.0x
MNKD Sector
Debt/Equity
MNKD 0.0x
vs
Sector Avg 0.6x
MNKD Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Mannkind Corp. Stock Overvalued? MNKD Valuation Analysis 2026

Based on fundamental analysis, Mannkind Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
-18.4%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Mannkind Corp. Balance Sheet: MNKD Debt, Cash & Liquidity

Current Ratio
1.87x
Quick Ratio
1.50x
Debt/Equity
N/A
Debt/Assets
108.0%
Interest Coverage
-0.19x
Long-term Debt
$318.7M

MNKD Revenue & Earnings Growth: 5-Year Financial Trend

MNKD 5-year financial data: Year 2021: Revenue $75.4M, Net Income -$57.2M, EPS N/A. Year 2022: Revenue $99.8M, Net Income -$57.2M, EPS $-0.26. Year 2023: Revenue $199.0M, Net Income -$80.9M, EPS $-0.32. Year 2024: Revenue $285.5M, Net Income -$87.4M, EPS $-0.34. Year 2025: Revenue $349.0M, Net Income -$11.9M, EPS $-0.04.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Mannkind Corp.'s revenue has grown significantly by 363% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.04 indicates the company is currently unprofitable.

MNKD Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-8.0%
Free cash flow / Revenue

MNKD Quarterly Earnings & Performance

Quarterly financial performance data for Mannkind Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $78.4M $13.2M $0.04
Q3 2025 $70.1M $668.0K $0.03
Q2 2025 $72.4M $668.0K $0.00
Q1 2025 $66.3M $10.6M $0.04
Q3 2024 $51.3M $1.7M $0.01
Q2 2024 $48.6M -$2.0M $-0.01
Q1 2024 $40.6M -$9.8M $-0.04
Q3 2023 $32.8M $1.7M $0.01

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Mannkind Corp. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$5.4M
Cash generated from operations
Stock Buybacks
$1.0M
Shares repurchased (TTM)
Capital Expenditures
$1.9M
Investment in assets
Dividends
None
No dividend program

MNKD SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Mannkind Corp. (CIK: 0000899460)

📋 Recent SEC Filings

Date Form Document Action
May 13, 2026 4 xslF345X06/ownership.xml View →
May 13, 2026 4 xslF345X06/ownership.xml View →
May 13, 2026 4 xslF345X06/ownership.xml View →
May 13, 2026 4 xslF345X06/ownership.xml View →
May 6, 2026 10-Q mnkd-20260331.htm View →

Frequently Asked Questions about MNKD

What is the AI rating for MNKD?

Mannkind Corp. (MNKD) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are MNKD's key strengths?

Claude: Revenue growing 22.2% YoY shows commercial traction. Adequate short-term liquidity with 1.87x current ratio. ChatGPT: 22.2% YoY revenue growth indicating solid demand momentum. Positive operating income with 11.1% margin and positive FCF.

What are the risks of investing in MNKD?

Claude: Negative stockholders' equity of -$59.2M indicates technical insolvency. Operating cash flow negative at -$5.4M; company cannot fund operations from business. ChatGPT: Negative stockholders' equity and sizable long-term debt load. Very thin net margin (1.7%) and sharply lower diluted EPS.

What is MNKD's revenue and growth?

Mannkind Corp. reported revenue of $90.2M.

Does MNKD pay dividends?

Mannkind Corp. does not currently pay dividends.

Where can I find MNKD SEC filings?

Official SEC filings for Mannkind Corp. (CIK: 0000899460) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MNKD's EPS?

Mannkind Corp. has a diluted EPS of $-0.05.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MNKD a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, Mannkind Corp. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MNKD stock overvalued or undervalued?

Valuation metrics for MNKD: ROE of N/A (sector avg: 15%), net margin of -18.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy MNKD stock in 2026?

Our dual AI analysis gives Mannkind Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MNKD's free cash flow?

Mannkind Corp.'s operating cash flow is $-5.4M, with capital expenditures of $1.9M. FCF margin is -8.0%.

How does MNKD compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -18.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.87 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% ANET 88% RDDT 88% KNSL 88% MGRE 88%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 8, 2026 | Data as of: 2026-03-31 | Powered by Claude AI